Orkambi
Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales
November 13, 2019Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma
After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …
Scotland turns down Vertex’s Orkambi
August 13, 2019Manufacturing and Production Orkambi, SMC, Scotland, Vertex, cystic fibrosis, pharma
The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …
Read the July/August edition of Pharmafocus online now!
June 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Orkambi, Trump, UK, brexit, generics, manufacturing compliance, pharma
The latest monthly edition of Pharmafocus, the July/August issue, is available to read for free online now!The UK remains split …
MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK
June 11, 2019Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing
MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …
Top Ten most popular articles on Pharmafile.com this week!
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer
It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …
Parents of children with cystic fibrosis start Orkambi buyers club
June 5, 2019Research and Development NHS, Orkambi, Vertex, cystic fibrosis
Parents of children with cystic fibrosis have started an Orkambi buyers’ club to import generic versions of Vertex’s drug from …
The price of access: Can the NHS afford Orkambi?
April 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing
The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
Vertex destroyed nearly 8,000 packs of Orkambi in 2018
March 28, 2019Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis
Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …
Vertex doubles Q4 profits, angering cystic fibrosis drug advocates in UK
February 11, 2019Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Despite ongoing controversy surrounding the currently stalled negotiations between Vertex and the NHS to make its cystic fibrosis (CF) drug …
Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission
January 22, 2019Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …
UK Ministers call on Vertex to speed up price negotiations
April 23, 2018Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical
After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …
Orkambi deemed not suitable for NHS use
July 27, 2016Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis
The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
Final Nice appraisal says no to cystic fibrosis drug, Orkambi
June 17, 2016Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi
March 23, 2016Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis
NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …
